Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.

BACKGROUND Patients with elevated prostate-specific antigen (PSA) and one or more previous negative transrectal ultrasound (TRUS) biopsy sessions are subject to diagnostic uncertainty due to TRUS-biopsy undersampling. Magnetic resonance (MR)-guided biopsy (MRGB) has shown high prostate cancer (PCa)-detection rates in studies with limited patient numbers. OBJECTIVE Determine the detection rate of (clinically significant) PCa for MRGB of cancer-suspicious regions (CSRs) on 3-T multiparametric MR imaging (MP-MRI) in patients with elevated PSA and one or more negative TRUS-biopsy sessions. DESIGN, SETTING, AND PARTICIPANTS Of 844 patients who underwent 3-T MP-MRI in our referral centre between March 2008 and February 2011, 438 consecutive patients with a PSA >4.0 ng/ml and one negative TRUS-biopsy session or more were included. MRGB was performed in 265 patients. Exclusion criteria were existent PCa, endorectal coil use, and MP-MRI for indications other than cancer detection. INTERVENTION Patients underwent MRGB of MP-MRI CSRs. MEASUREMENTS (Clinically significant) MRGB cancer-detection rates were determined. Clinically significant cancer was defined by accepted (i.a. Epstein and d'Amico) criteria based on PSA, Gleason score, stage, and tumour volume. Follow-up PSA and histopathology were collected. Sensitivity analysis was performed for patients with MP-MRI CSRs without MRGB. RESULTS AND LIMITATIONS In a total of 117 patients, cancer was detected with MRGB (n=108) or after negative MRGB (n=9). PCa was detected in 108 of 438 patients (25%) and in 41% (108 of 265) of MRGB patients. The majority of detected cancers (87%) were clinically significant. Clinically significant cancers were detected in seven of nine (78%) negative MRGB patients in whom PCa was detected during follow-up. Sensitivity analysis resulted in increased cancer detection (47-56%). Complications occurred in 0.2% of patients (5 of 265). CONCLUSIONS In patients with elevated PSA and one or more negative TRUS-biopsy sessions, MRGB of MP-MRI CSRs had a PCa-detection rate of 41%. The majority of detected cancers were clinically significant (87%).

[1]  M. Kattan,et al.  Nomogram use for the prediction of indolent prostate cancer , 2007, Cancer.

[2]  Alan W Partin,et al.  Characteristics of insignificant clinical T1c prostate tumors , 2004, Cancer.

[3]  Thomas Hambrock,et al.  Computer-assisted analysis of peripheral zone prostate lesions using T2-weighted and dynamic contrast enhanced T1-weighted MRI , 2010, Physics in medicine and biology.

[4]  Pingkun Yan,et al.  Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. , 2011, The Journal of urology.

[5]  William J Catalona,et al.  Serial biopsy results in prostate cancer screening study. , 2002, The Journal of urology.

[6]  S. Misra,et al.  Evaluation of a robotic technique for transrectal MRI-guided prostate biopsies , 2011, European Radiology.

[7]  D. Gleason,et al.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. , 1974, The Journal of urology.

[8]  Fritz H. Schröder,et al.  Evaluation of the Digital Rectal Examination as a Screening Test for Prostate Cancer , 1998 .

[9]  Thomas Hambrock,et al.  Thirty-Two-Channel Coil 3T Magnetic Resonance-Guided Biopsies of Prostate Tumor Suspicious Regions Identified on Multimodality 3T Magnetic Resonance Imaging: Technique and Feasibility , 2008, Investigative radiology.

[10]  C C Schulman,et al.  Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? , 2001, The Journal of urology.

[11]  Y. Yamashita,et al.  Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation , 2010, European Radiology.

[12]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[13]  K. Taari,et al.  Magnetic resonance imaging of prostatic cancer: Does detection vary between high and low gleason score tumors? , 2000, The Prostate.

[14]  Yipeng Hu,et al.  Characterizing clinically significant prostate cancer using template prostate mapping biopsy. , 2011, The Journal of urology.

[15]  J. Ferlay,et al.  Estimates of cancer incidence and mortality in Europe in 2008. , 2010, European journal of cancer.

[16]  Thomas Hambrock,et al.  Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen. , 2010, The Journal of urology.

[17]  M. Bock,et al.  Automatic passive tracking of an endorectal prostate biopsy device using phase‐only cross‐correlation , 2008, Magnetic resonance in medicine.

[18]  François Cornud,et al.  Multiparametric magnetic resonance imaging for the detection and localization of prostate cancer: combination of T2‐weighted, dynamic contrast‐enhanced and diffusion‐weighted imaging , 2011, BJU international.

[19]  D. Beyersdorff,et al.  MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results. , 2005, Radiology.

[20]  Rodolfo Montironi,et al.  Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. , 2007, European urology.

[21]  S. Madersbacher,et al.  Re: Thomas Hambrock, Caroline Hoeks, Christina Hulsbergen-van de Kaa, et al. Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. Eur Urol 2012;61:17 , 2012, European urology.

[22]  Ralph Strecker,et al.  Areas suspicious for prostate cancer: MR-guided biopsy in patients with at least one transrectal US-guided biopsy with a negative finding--multiparametric MR imaging for detection and biopsy planning. , 2011, Radiology.

[23]  B. Kiefer,et al.  Prostate biopsy in the supine position in a standard 1.5-T scanner under real time MR-imaging control using a MR-compatible endorectal biopsy device , 2006, European Radiology.

[24]  Heinz-Peter Schlemmer,et al.  MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. , 2006, European urology.

[25]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Ralph Strecker,et al.  Areas Suspicious for Prostate Cancer : MR – guided Biopsy in Patients with at Least One Transrectal US-guided Biopsy with a Negative Finding — Multiparametric MR Imaging for Detection and Biopsy Planning 1 , 2011 .

[27]  D. Schilling,et al.  MRI-guided prostate biopsy detects clinically significant cancer: analysis of a cohort of 100 patients after previous negative TRUS biopsy , 2012, World Journal of Urology.

[28]  John E Tomaszewski,et al.  Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era , 2002, Cancer.

[29]  J. Patard,et al.  Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy. , 2009, European urology.

[30]  P. J. van der Maas,et al.  Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. , 1999, Journal of the National Cancer Institute.

[31]  H Ballentine Carter,et al.  Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. , 2008, European urology.

[32]  A S Whittemore,et al.  Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer , 1993, Cancer.

[33]  Thomas Hambrock,et al.  Prospective assessment of prostate cancer aggressiveness using 3-T diffusion-weighted magnetic resonance imaging-guided biopsies versus a systematic 10-core transrectal ultrasound prostate biopsy cohort. , 2012, European urology.